Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset

References

• Bell EH, Pugh SL, McElroy JP, et al. Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era a correlative analysis based on nrg oncology RTOG 0525. JAMA Oncol. 2017;3(6):784–792.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466.
   PubMed Web of Science ®Google Scholar
• Theeler BJ, Gilbert MR. Advances in the treatment of newly diagnosed glioblastoma. BMC Med. 2015;13(1):1–11.
   PubMedGoogle Scholar
• Han S, Liu Y, Cai SJ, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122(11):1580–1589.
   PubMed Web of Science ®Google Scholar
• An Z, Aksoy O, Zheng T, et al. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37(12):1561–1575.
   PubMed Web of Science ®Google Scholar
• Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol. 2019;21(2):167–178.
   PubMed Web of Science ®Google Scholar
• Liang P, Chai Y, Zhao H, et al. Predictive analyses of prognostic-related immune genes and immune infiltrates for glioblastoma. Diagnostics. 2020;10(3):177.
   Web of Science ®Google Scholar
• Wei J, Marisetty A, Schrand B, et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019;129(1):137–149.
   PubMed Web of Science ®Google Scholar
• Shen M, Chen G, Xie Q, et al. Association between PD-L1 expression and the prognosis and clinicopathologic features of renal cell carcinoma: a systematic review and meta-analysis. Urol Int. 2020;1–9. DOI:10.1159/000506296
   Web of Science ®Google Scholar
• Girolami I, Pantanowitz L, Mete O, et al. Programmed Death-Ligand 1 (PD-L1) Is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma. Endocr Pathol. 2020;31(3):291–300.
   PubMed Web of Science ®Google Scholar
• Lenouvel D, Má G-M, Ruiz-Ávila I, et al. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: a systematic review and comprehensive meta-analysis. Oral Oncol. 2020;106:104722.
   PubMed Web of Science ®Google Scholar
• Cai H, Zhang H, Prognostic JY. Clinicopathological value of programmed cell death ligand1 expression in patients with small cell lung cancer: a meta-analysis. Front Oncol. 2020;10:1–9.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (reprinted from annals of internal medicine). Phys Ther. 2009;89(9):873–880.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):1–16.
   PubMedGoogle Scholar
• Von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15(1):1–8.
   PubMedGoogle Scholar
• Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and Fill: a simple funnel-plot-based method. Biometrics. 2000;56(2):455–463.
   PubMed Web of Science ®Google Scholar
• Lin L, Chu H, Murad MH, et al. Empirical comparison of publication bias tests in meta-analysis. J Gen Intern Med. 2018;33(8):1260–1267.
   PubMed Web of Science ®Google Scholar
• Takashima Y, Kawaguchi A, Kanayama T, et al. Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma. Oncotarget. 2018;9(27):19065–19078.
   PubMedGoogle Scholar
• Su L, Guo W, Lou L, et al. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma. Mol Carcinog. 2020;59(5):520–532.
   PubMed Web of Science ®Google Scholar
• Knudsen AM, Rudkjøbing SJ, Sørensen MD, et al. Expression and prognostic value of the immune checkpoints galectin-9 and PD-L1 in glioblastomas. J Neuropathol Exp Neurol. 2021;80(6):541–551.
   PubMed Web of Science ®Google Scholar
• Zeng J, Zhang XK, Chen HD, et al. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget. 2016;7(8):8944–8955.
   PubMedGoogle Scholar
• Long S, Li M, Liu J, et al. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling. Aging (Albany NY). 2020;12(8):7112–7128.
   PubMedGoogle Scholar
• Han J, Hong Y, Lee YS. PD-L1 expression and combined status of PD-L1/PD-1-positive tumor infiltrating mononuclear cell density predict prognosis in glioblastoma patients. J Pathol Transl Med. 2017;51(1):40–48.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18(2):195–205.
   PubMed Web of Science ®Google Scholar
• Liu Y, Carlsson R, Ambjørn M, et al. Issazadeh-Navikas S. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci. 2013;33(35):14231–14245.
   PubMed Web of Science ®Google Scholar
• Jan CI, Tsai WC, Harn HJ, et al. Predictors of response to autologous dendritic cell therapy in glioblastoma multiforme. Front Immunol. 2018;9:727.
   PubMed Web of Science ®Google Scholar
• Lee KS, Lee K, Yun S, et al. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. J Neurooncol. 2018;136(3):453–461.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17(8):1064–1075.
   PubMed Web of Science ®Google Scholar
• Pratt D, Dominah G, Lobel G, et al. Programmed death ligand 1 Is a negative prognostic marker in recurrent isocitrate dehydrogenase-wildtype glioblastoma. Neurosurgery. 2019;85(2):280–288.
   PubMedGoogle Scholar
• Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142.
   PubMed Web of Science ®Google Scholar
• Yang D, Shen J, Fan J, et al. Paracellular permeability changes induced by multi-walled carbon nanotubes in brain endothelial cells and associated roles of hemichannels. Toxicology. 2020;440:152491.
   PubMed Web of Science ®Google Scholar
• Gaete PS, Lillo MA, Figueroa XF. Functional role of connexins and pannexins in the interaction between vascular and nervous system. J Cell Physiol. 2014;229(10):1336–1345.
   PubMed Web of Science ®Google Scholar
• Carson MJ, Doose JM, Melchior B, et al. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213(1)::48–65.
   PubMedGoogle Scholar
• Müller C, Holtschmidt J, Auer M, et al. Cancer: hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6(247):1–10.
   Web of Science ®Google Scholar
• Chen Z, Hambardzumyan D, Darby J. Immune microenvironment in glioblastoma subtypes. Front Immunol. 2018;9:1–8.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677–704.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage iii non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;34:833–842.
   PubMed Web of Science ®Google Scholar
• Kurz SC, Cabrera LP, Hastie D, et al. inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018;91(14):E1355–E1359.
   PubMed Web of Science ®Google Scholar
• Lukas RV, Rodon J, Becker K, et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018;140(2):317–328.
   PubMed Web of Science ®Google Scholar
• Caccese M, Indraccolo S, Zagonel V, et al. PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: a concise review. Crit Rev Oncol Hematol. 2019;135:128–134.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Kaley TJ, Dietrich J, et al. Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: an update. J Clin Oncol. 2017;35(15_suppl):2042.
   Google Scholar
• Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003–1010.
   PubMed Web of Science ®Google Scholar
• Xia W, Zhu J, Tang Y, et al. PD-L1 Inhibitor Regulates the miR-33a-5p/PTEN signaling pathway and can be targeted to sensitize glioblastomas to radiation. Front Oncol. 2020;10:1–12.
   PubMed Web of Science ®Google Scholar
• Zhang H, Dai Z, Wu W, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40(1):1–22.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–327.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567.
   PubMed Web of Science ®Google Scholar
• Bronsart E, Derangere V, Boone M, et al. PD-L1 and IL17 expression in tumor infiltrating lymphocytes are opposite prognostic factors in glioblastoma. Ann Oncol. 2016;27:vi104.
   Web of Science ®Google Scholar
• Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34(34):4102–4109.
   PubMed Web of Science ®Google Scholar
• McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2(1):46–54.
   PubMed Web of Science ®Google Scholar
• Haffner MC, Guner G, Taheri D, et al. Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am J Pathol. 2018;188(6):1478–1485.
   PubMed Web of Science ®Google Scholar
• Jomrich G, Silberhumer GR, Marian B, et al. Programmed death-ligand 1 expression in rectal cancer. Eur Surg - Acta Chir Austriaca. 2016;48(6):352–356.
   Web of Science ®Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Cui G, Ren X, et al. A novel four-gene signature associated with immune checkpoint for predicting prognosis in lower-grade glioma. Front Oncol. 2020;10:2392.
   Web of Science ®Google Scholar
• Xue S, Song G, Yu J. The prognostic significance of PD-L1 expression in patients with glioma: a meta-analysis. Sci Rep. 2017;7(1):1–8.
   PubMed Web of Science ®Google Scholar